TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05806749

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Donor CD34+, CD3+. and belumosudil
Description: Immediately after living donor kidney transplantation, subjects will begin a conditioning regimen of rATG and total lymphoid irradiation. An infusion of at least 8 X106 donor CD34 cells/kg recipient weight and of at least 10 X106 donor CD3 cells/kg recipient weight will then be given. A triple immunosuppressive regimen of tacrolimus, corticosteroids, and mycophenolate will be utilized.~Corticosteroids will be given on a tapering schedule from day 0 through the first four months. Tacrolimus will be given on a tapering schedule from day 1 through month 18. Mycophenolate will be given at a fixed dose from day 11 through month 12.~Subjects will receive belumosudil 200 mg by mouth daily from day 28 following the kidney transplant through month 24.
Study: NCT06489873

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator (Lutein, zeaxanthin, and fish oil supplement (LZF)
Description: Each participant will be assigned to t a LZF supplement daily for six months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Each participant will be assigned to take a placebo supplement daily for six months
Study: NCT05609084

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Speech therapy
Description: Patients will connect on an interface to pratice speech therapy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Speech therapy assessment
Description: Patients will be followed by an speech therapist

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Speech therapy assessment
Description: Patients will be followed by an speech therapist
Study: NCT06271811

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flossing band
Description: The application of flossing to the knee commences with a preliminary evaluation of the joint range of motion and pain perception. The band is wrapped around the knee, starting with an approximate tension of 50% for the first wrap and escalating to a tension of 60-80% in subsequent wraps. It\&#39;s essential to overlap the band with each wrap, moving from a distal to the proximal direction (bottom to top), which aids in enhancing drainage. Continuous monitoring of the patient is critical to ensure that excessive pressure is not being applied. This can be achieved by palpating the pulse on the dorsum of the foot or inner ankle, and observing if the skin regains its normal color after pressing the area with fingers. Should the patient experience strong tingling or pain, the bandage must be immediately removed. The duration of the band's application varies between 2 to 5 minutes, depending on patient tolerance, a methodology informed by existing research.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: The intervention protocol is centered on neuromuscular training, targeting the strengthening of key muscle groups including the quadriceps, hamstrings, and hip abductors, which are vital for knee stabilization. This approach is supported by previous research, emphasizing the importance of these muscle groups in knee joint health. Complementing this, proprioceptive exercises, such as single-leg balances and controlled knee bends, were incorporated to enhance joint position sense, aligning with the guidelines set forth by Powers et al., 2010.~The intensity of these exercises is progressively increased, tailored to each patient's tolerance and improvement. The protocol stipulates two sessions per week over eight weeks.
Study: NCT04843930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKL-T01
Description: AKL-T01 will be administered as a 6-week intervention. It is an algorithmically delivered iPad-based video game designed to improve cognitive health by targeting attention and attentional control processes.
Study: NCT04997954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MediCabilis CBD oil
Description: The investigational product (MediCabilis 5% (50mg/ml) CBD Oil) will be supplied by BOD Australia, an Australian licensed manufacturer of medical grade cannabis.~The main components of MediCabilis 5% (50 mg/mL) CBD extract in MCT Oil are:~* Cannabis sativa L. dry extract~* Medium chain triglycerides (Ph Eur 0868) which are added in order to adjust the active constituent (cannabidiol) to the target content.~Each mL of MediCabilis provides:~* 50 mg of Cannabidiol (CBD+CBDA)~* Less than 2 mg tetrahydrocannabinol (THC)~* Non-active ingredient: Medium Chain Triglycerides (MCT) oil sourced from coconut
Study: NCT04755101

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EPS, electro-anatomical mapping, ARGP ablation, and pharmacological evaluation.
Description: EPS and electro-anatomical mapping of the right atrium and the surrounding veins. A target line (TL) is traced at the posteroseptal side of the junction, between the right atrium and superior vena cava, facing the mid and caudal parts of the right superior pulmonary vein antrum on the right heart cavities on a CT image imported into the CARTO system. This map will be carefully merged with the CT image and the TL will be visible. Sequential ablations will be delivered along theTL until the procedure endpoint is reached. Pharmacological evaluation.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: EPS, electro-anatomical mapping, and pharmacological evaluation.
Description: EPS and electro-anatomical mapping of the right atrium and the surrounding veins. A target line (TL) is traced at the posteroseptal side of the junction, between the right atrium and superior vena cava, facing the mid and caudal parts of the right superior pulmonary vein antrum on the right heart cavities on a CT image imported into the CARTO system. This map will be carefully merged with the CT image and the TL will be visible. No ablation is performed (sham). Pharmacological evaluation.
Study: NCT05724355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib Isetionate Tablets, Camrelizumab
Description: Dalpiciclib, D1-21, po, 150mg, qd, Q4W. Camrelizumab, iv, 200mg, D1, Q3W.
Study: NCT00669786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Menopausal Gonadotropin (HMG) & - Recombinant Follicle Stimulating Hormone (r-FSH)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Menopausal Gonadotropin (HMG) & - Recombinant Follicle Stimulating Hormone (r-FSH)
Study: NCT06275152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Remote Ischemic Conditioning
Description: The sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
Study: NCT04920864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Repetitive transcranial magnetic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Repetitive transcranial magnetic stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Repetitive transcranial magnetic stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Repetitive transcranial magnetic stimulation
Study: NCT06567678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG oral tablet twice daily
Description: Blood samples will be collected from participants in 2 separate instances. Initially, a baseline VerifyNow P2Y12 PRU and Aspirin reaction unit test assay, followed by a subsequent repeat test 2-week after a 2-week, colchicine 0.5mg oral tablet twice-daily
Study: NCT05917639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitruvian plot
Description: Visual (magnitude, uncertainty) and written (magnitude) communication tool / interventional decision-making aid tool

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kilim plot
Description: Visual (uncertainty) and written (magnitude) communication tool / interventional decision-making aid tool

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Summary of findings table
Description: Written (magnitude, uncertainty) communication tool / interventional decision-making aid tool
Study: NCT06118268

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS (Active)
Description: The present study is a double-blind, randomized clinical trial that will examine if iTBS applied to DMPFC improves social cognitive performance compared to sham stimulation~DMPFC-iTBS will be administered using the MagPro R30 stimulator equipped with a Cool-B70 coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Visor 2.0 system (Advanced Neuro Technologies Enschede, Netherlands).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: iTBS (Sham)
Description: DMPFC-iTBS will be administered using the MagPro R30 stimulator equipped with a Cool-B70 coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Visor 2.0 system (Advanced Neuro Technologies Enschede, Netherlands).
Study: NCT04369014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etomidate anesthesia
Description: etomidate is used for induction and maintenance of general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol anesthesia
Description: propofol is used for induction and maintenance of general anesthesia
Study: NCT05523414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SKY
Description: The SKY intervention will be administered in-person over three sessions spread over three consecutive days by qualified instructors. Participants will then be followed up over eight weeks' time, where they will be given the option to attend daily 35 minute breathwork sessions, again, guided by experienced instructors. Participants will be required to log whether or not they practiced for each day in the eight-week period. They will also receive intermittent reminders about their daily practice during the 8-week follow-up period.
Study: NCT05207514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoxel M
Description: 75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere
Description: 75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with doxorubicin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with doxorubicin.
Study: NCT06344390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Take pentoxifylline 0.4 g twice daily
Study: NCT06336616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Activation
Description: Participants will be taught to identify meaningful activities, set goals, use environmental cues, self-reward, to identify barriers and facilitators, and learn new skills to support them to develop self-management skills and new habits.
Study: NCT06113601

Intervention type: OTHER
Intervention: There is no intervention.
Description: There is no intervention in the study.

Intervention type: OTHER
Intervention: There is no intervention.
Description: There is no intervention in the study.
Study: NCT05597657

Intervention type: OTHER
Group type: OTHER
Intervention: Fluid administration (Fresenius Kabi Sodium Chloride 0.9%)
Description: All participants in substudy 2 will be administered 2 liters of isotonic saline infusion (Fresenius Kabi Sodium Chloride 0.9%) intravenously. CMR and echocardiography will be performed before and after infusion.
Study: NCT05056779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Participants will receive loading dose of 60 milligram (2×30 mg) subcutaneous (SC) injection of nemolizumab at baseline. Thereafter 30 mg nemolizumab will be administered via single SC injection once in 4 week (Q4W) up to week 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD14152 placebo
Description: Participants will receive loading dose of 60 mg (2×30 mg) SC injection of placebo at baseline. Thereafter 30 mg placebo will be administered via single SC injection Q4W up to week 12.
Study: NCT04816513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Ustekinumab will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab will be administered as SC injection.
Study: NCT04885556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tampon-like device for absorption of sexual fluids
Description: Subjects will insert a tampon-like device to absorb sexual fluids after intercourse

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tampon-like device for absorption of sexual fluids
Description: Subjects will insert a tampon-like device to absorb sexual fluids after intercourse
Study: NCT05980182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Application
Description: Self-directed application (app) that is downloaded to the participant's personal device. The app contains five informational videos, that provide an orientation to the content on the app, and discuss what colorectal cancer is, and the type of CRC screening tests that are available as well as a video with a personal history. There is a a National Cancer Institute (NCI) risk calculation tool, and a family history infographic. Once the videos have been viewed participants have the option to indicate if they wish to receive a call from the healthcare clinic to discuss scheduling an appointment for screening.
Study: NCT05159089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Socioecological model apply to reduce physical activity drop out in type 2 diabetes patients
Description: To implement this model this intervention aims to address three key elements: 1) prepare the user; 2) structure the action; and 3) design the context.~These goals will be worked in each session of Nordic Walking during the warm-up and cool-down and, if necessary, during the session (as long as it's non-stop or slowing down).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nordic Walking
Description: Sessions will be progressive: the first month will long 30 minutes, the second month 35 minutes, and the third month 40 minutes (without 10 minutes warm-up and 10 minutes cool-down each session). The track will not have more than 100 accumulate high and will allow doing 5 kilometers without stopping. The meeting point will be between the Biomedical Research Park (Barcelona) and Hospital del Mar (nearby CAP Sant Joan). All sessions will be conducted by an instructor of nordic walking physiotherapists.
Study: NCT06545981

Intervention type: OTHER
Intervention: Lumbar puncture and administration of medication
Description: Patients with idiopathic intracranial hypertension will receive lumbar puncture and will be given medication to reduce intracranial pressure by neurologists. The lumbar puncture and the administration of medication are not part of this study, patients would also receive these without participating in the study.
Study: NCT06643884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Laser Administration
Study: NCT04258488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban Oral Tablet
Description: For 12months, Rivaroxaban oral tablet 20mg once daily For renal disorder subjects_creatinine clearance 15-49 mL/min, 15mg once daily
Study: NCT05388721

Intervention type: OTHER
Intervention: Clinical data and specimen collection
Description: Questionnaire survey and clinical data was conducted when pregnant women were enrolled in the first trimester, and blood and urine were collected. Furthermore, we will follow up the pregnant women until delivery, blood and urine were collected during the third trimester (after 28 weeks), and clinical information was collected.~Umbilical cord blood and placental tissue will be collected if possible.

Intervention type: OTHER
Intervention: Clinical data and specimen collection
Description: Questionnaire survey and clinical data was conducted when pregnant women were enrolled in the first trimester, and blood and urine were collected. Furthermore, we will follow up the pregnant women until delivery, blood and urine were collected during the third trimester (after 28 weeks), and clinical information was collected.~Umbilical cord blood and placental tissue will be collected if possible.
Study: NCT05100186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.4 MG [Dextenza]
Description: Dextenza
Study: NCT00914004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine HCl 50 mg Tablets Cord Laboratories

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc
Study: NCT05952635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tip bendable suction ureteral access sheath
Description: Patient use tip bendable suction ureteral access sheath during flexible ureteroscopy to see if flexible ureteroscopy with S-UAS offers the better treatment outcomes in terms of clinical effectiveness and post-operative complications.
Study: NCT06495203

Intervention type: DRUG
Intervention: anti-VEGF treatment
Description: Follow clinical practice/administration

Intervention type: DRUG
Intervention: anti-VEGF treatment
Description: Follow clinical practice/administration

Intervention type: DRUG
Intervention: anti-VEGF treatment
Description: Follow clinical practice/administration

Intervention type: DRUG
Intervention: anti-VEGF treatment
Description: Follow clinical practice/administration

Intervention type: DRUG
Intervention: anti-VEGF treatment
Description: Follow clinical practice/administration
Study: NCT04813380

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual immunotherapy
Description: Sublingual immunotherapy give to allergic rhinitis patients for treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sublingual immunotherapy
Description: Sublingual immunotherapy give to allergic rhinitis patients for treatment
Study: NCT05399680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S.M.A.R.T. RADIANZ™ Vascular Stent System
Description: The S.M.A.R.T. RADIANZ™ Vascular Stent System is designed to deliver the S.M.A.R.T.™ self-expanding stent (S.M.A.R.T.™ stent) to the iliac arteries, superficial femoral arteries and/or proximal popliteal arteries using a 6F (2.0 mm) sheathed delivery system introduced through the radial artery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BRITE TIP RADIANZ™ Guiding Sheath
Description: BRITE TIP RADIANZ™ is a catheter guiding sheath that facilitates percutaneous entry of an intravascular device into the peripheral vasculature through the radial artery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SABERX RADIANZ™ PTA Balloon Catheter
Description: SABERX RADIANZ™ is a catheter with a distal inflatable balloon.
Study: NCT04965350

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)
Description: sterile solution for intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)
Description: sterile solution for intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)
Description: sterile solution for intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)
Description: sterile solution for intramuscular injection
Study: NCT05864664

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wide awake local anaesthesia no tourniquet technique
Description: Patient awake with no form of sedation or analgesia~* A mixture of lidocaine, adrenaline, normal saline, bicarbonate is used to get 40-50ml solution~* Injection is performed around incision site - superficial to deep including periosteum~* Incision is performed in the normal fashion~* Plate and screws are removed and incision is closed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wide awake local anaesthesia no tourniquet technique
Description: Patient awake with no form of sedation or analgesia~* A mixture of lidocaine, adrenaline, normal saline, bicarbonate is used to get 40-50ml solution~* Injection is performed around incision site - superficial to deep including periosteum~* Incision is performed in the normal fashion~* Plate and screws are removed and incision is closed
Study: NCT05261893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elongation Longitudinaux Avec Decoaption Osteo Articulaire
Description: It creates tension in the spine and stretch the fascia and is a myofascial stretch technique and manual physical therapy tool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Facilitation Stretching
Description: Post Facilitation Stretching effectively decreases hamstring muscle tightness while also increasing popliteal angle range. Post-facilitation exercise can help to relieve knee pain. It effectively raises ROM or aligns collagen fibers due to the muscle contraction performed immediately before stretching.
Study: NCT05183022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total30 Sphere Contact Lenses
Description: Participants will be refit into Total30 Sphere contact lenses and followed for 1 month.